Intro­duc­tion to GalNAc-L96

GalNAc-L96 (CAS 1159408-62-4) is a tri­anten­nary N-acetyl­­galac­­tosamine (GalNAc) lig­and pri­mar­i­ly used for the syn­the­sis of GalNAc-siR­­NA. GalNAc is a spe­cif­ic lig­and for ASG­PR (Asialo­gly­co­pro­tein Recep­tor), enabling liv­er-tar­get­ed deliv­ery, which is a cru­cial aspect of mod­ern RNA deliv­ery tech­nol­o­gy. Appli­ca­tions and Advan­tages of GalNAc-L96
  1. Pre­cise Liv­er-Tar­get­ed Deliv­ery : ASG­PR is high­ly expressed on liv­er cell sur­faces, allow­ing siR­NA, anti­sense oligonu­cleotides (ASO), or oth­er nucle­ic acid drugs con­ju­gat­ed with GalNAc-L96 to effi­cient­ly enter liv­er cells and enhance ther­a­peu­tic effects.
  2. Enhanced Bioavail­abil­i­ty of siR­NA : Tra­di­tion­al siR­NA deliv­ery meth­ods (such as lipid nanopar­ti­cles, LNPs) often lead to non-spe­­cif­ic dis­tri­b­u­tion, where­as GalNAc-con­ju­­gat­ed siR­NA (GalNAc-siR­­NA) enables more effi­cient and safer RNA inter­fer­ence (RNAi) therapy.
  3. Reduced Sys­temic Tox­i­c­i­ty : Due to the high speci­fici­ty of GalNAc deliv­ery, com­pared to LNPs, GalNAc-siR­­NA exhibits low­er immuno­genic­i­ty and reduced side effects, mak­ing it a pre­ferred strat­e­gy for RNA drug development.
  4. Improved Sta­bil­i­ty and Opti­mized Phar­ma­co­ki­net­ics : By opti­miz­ing the struc­ture of GalNAc-L96, its affin­i­ty for ASG­PR can be enhanced, there­by increas­ing hepat­ic cell uptake and pro­long­ing in vivo half-life.

Watson’s Unique Advan­tages in the GalNAc Field

  1. Advanced Syn­the­sis Tech­niques and Puri­ty Control
  • Wat­son lever­ages cut­t­ing-edge gly­co­chem­istry and nucle­ic acid mod­i­fi­ca­tion tech­nolo­gies to pro­vide high-puri­­ty, high-qual­i­­ty GalNAc-L96 and its deriv­a­tives, ensur­ing opti­mal out­comes in RNAi and ASO drug development.
  1. Com­pre­hen­sive Sup­port from Lab to Indus­tri­al Scale
  • Wat­son not only sup­plies small-scale research-grade prod­ucts but also has pilot and indus­tri­al-scale pro­duc­tion capa­bil­i­ties, meet­ing the demands from ear­­ly-stage research to clin­i­cal production.
  • Strict adher­ence to qual­i­ty man­age­ment sys­tems (ISO cer­ti­fi­ca­tion) ensures prod­uct qual­i­ty and stability.
  1. Strong Tech­ni­cal Exper­tise and Indus­try Recognition
  • With years of expe­ri­ence in gly­co­con­ju­gates and RNA deliv­ery, Wat­son col­lab­o­rates with lead­ing phar­ma­ceu­ti­cal and biotech­nol­o­gy com­pa­nies world­wide, dri­ving advance­ments in RNA therapeutics.
  • Watson’s high-end cus­tomiza­tion and inno­v­a­tive syn­the­sis capa­bil­i­ties make it a key glob­al part­ner in RNA deliv­ery technologies.

Con­clu­sion

As a core lig­and for RNA-tar­get­ed deliv­ery, GalNAc-L96 plays a vital role in siR­NA and ASO ther­a­pies. With cut­t­ing-edge syn­the­sis tech­nolo­gies, strict qual­i­ty con­trol, and strong cus­tomiza­tion capa­bil­i­ties, Wat­son holds a dis­tinct com­pet­i­tive advan­tage in this field, sup­port­ing break­throughs in RNA deliv­ery tech­nol­o­gy. If you are inter­est­ed in GalNAc-relat­ed prod­ucts or RNA deliv­ery solu­tions, feel free to con­tact Wat­son for more information ! 

Sales Link

GalNAc-L96 – A Key Mol­e­cule for Effi­cient RNA Tar­get­ed Delivery